Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
UBS
Chinese Patent Office
QuintilesIMS
Covington

Generated: September 16, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,608,616

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,608,616 protect, and when does it expire?

Patent 7,608,616 protects DORAL and is included in one NDA.

Summary for Patent: 7,608,616
Title:Methods for reducing the risk of an adverse drug interaction in a patient suffering from insomnia
Abstract:Disclosed herein is a method for treating a patient with Quazepam that reduces the risk of an adverse interaction between the Quazepam and drug that is a substrate of the cytochrome P450 enzyme isoform 2B6 (CYP2B6 substrate drug), e.g., Bupropion. The method includes determining if the patient to be treated with Quazepam is being treated with a CYP2B6 substrate drug, and prescribing or treating the patient with Quazepam based on the determination.
Inventor(s): Cartt; Steve (Union City, CA)
Assignee: Questcor Pharmaceuticals, Inc. (Union City, CA)
Application Number:12/132,575
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 7,608,616

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Galt Pharms DORAL quazepam TABLET;ORAL 018708-003 Feb 26, 1987 DISCN No No   Try a Free Trial   Try a Free Trial METHOD FOR TREATING INSOMNIA WHILE REDUCING THE RISK OF AN ADVERSE DRUG INTERACTION   Try a Free Trial
Galt Pharms DORAL quazepam TABLET;ORAL 018708-001 Dec 27, 1985 RX Yes Yes   Try a Free Trial   Try a Free Trial METHOD FOR TREATING INSOMNIA WHILE REDUCING THE RISK OF AN ADVERSE DRUG INTERACTION   Try a Free Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Johnson and Johnson
Federal Trade Commission
Cipla
Daiichi Sankyo
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.